Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linong Ji

Showing results (351-360 of 587) with videos related to

Pageof 59
Sort By:
Diabetes, Obesity & Metabolism|March 2, 2023
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel studyLinong Ji, Yibin Lu, Qifu Li, et al.
Endocrine|April 15, 2024
Predictive value of postprandial C-peptide for utilizing multiple daily injection therapy in type 2 diabetesWei Liu, Ying Gao, Rui Zhang, et al.
Journal of Diabetes Investigation|August 22, 2023
Machine learning for the prediction of atherosclerotic cardiovascular disease during 3-year follow up in Chinese type 2 diabetes mellitus patientsJinru Ding, Yingying Luo, Huwei Shi, et al.
Clinical Chemistry|March 5, 2015
Investigation of 2 models to set and evaluate quality targets for hb a1c: biological variation and sigma-metricsCas Weykamp, Garry John, Philippe Gillery, et al.
Asia Pacific Journal of Clinical Nutrition|December 24, 2015
Comparison of the dietary intakes of individuals with and without type 1 diabetes in ChinaLindsay M Jaacks, Shufa Du, Michelle A Mendez, et al.
Diabetes, Obesity & Metabolism|October 12, 2023
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN ChinaLinong Ji, A J Ahmann, B Ahrén, et al.
Endocrine Research|June 12, 2019
Factors Associated with Acute Complications among Individuals with Type 1 Diabetes in China: The 3C StudyWei Liu, Helen C McGuire, Katarzyna Kissimova-Skarbek, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 15, 2024
ISIS 449884 Injection Add-On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical StudyLinong Ji, Leili Gao, Zhikai Feng, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 29, 2024
Publisher Correction to: ISIS 449884 Injection Add‑On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double‑Blind, Placebo‑Controlled, Phase II Clinical StudyLinong Ji, Leili Gao, Zhikai Feng, et al.
Eclinicalmedicine|August 25, 2021
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b studyLinong Ji, Hongwei Jiang, Pei An, et al.
Pageof 59

Showing results (351-360 of 587) with videos related to

Sort By:
Pageof 59
Diabetes, Obesity & Metabolism|March 2, 2023
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel studyLinong Ji, Yibin Lu, Qifu Li, et al.
Endocrine|April 15, 2024
Predictive value of postprandial C-peptide for utilizing multiple daily injection therapy in type 2 diabetesWei Liu, Ying Gao, Rui Zhang, et al.
Journal of Diabetes Investigation|August 22, 2023
Machine learning for the prediction of atherosclerotic cardiovascular disease during 3-year follow up in Chinese type 2 diabetes mellitus patientsJinru Ding, Yingying Luo, Huwei Shi, et al.
Clinical Chemistry|March 5, 2015
Investigation of 2 models to set and evaluate quality targets for hb a1c: biological variation and sigma-metricsCas Weykamp, Garry John, Philippe Gillery, et al.
Asia Pacific Journal of Clinical Nutrition|December 24, 2015
Comparison of the dietary intakes of individuals with and without type 1 diabetes in ChinaLindsay M Jaacks, Shufa Du, Michelle A Mendez, et al.
Diabetes, Obesity & Metabolism|October 12, 2023
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN ChinaLinong Ji, A J Ahmann, B Ahrén, et al.
Endocrine Research|June 12, 2019
Factors Associated with Acute Complications among Individuals with Type 1 Diabetes in China: The 3C StudyWei Liu, Helen C McGuire, Katarzyna Kissimova-Skarbek, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 15, 2024
ISIS 449884 Injection Add-On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical StudyLinong Ji, Leili Gao, Zhikai Feng, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 29, 2024
Publisher Correction to: ISIS 449884 Injection Add‑On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double‑Blind, Placebo‑Controlled, Phase II Clinical StudyLinong Ji, Leili Gao, Zhikai Feng, et al.
Eclinicalmedicine|August 25, 2021
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b studyLinong Ji, Hongwei Jiang, Pei An, et al.
Pageof 59